News | Mammography | June 30, 2017

Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50

Nation’s largest independent provider of breast screening services recognized for improving technology, leading to fewer recalls and higher retention rates

Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50

June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the Dallas Business Journal. Rankings of the publication’s third annual research project were based on both private and public companies with revenue between $25 million and $750 million. Fifty-three companies that met the annual revenue requirements in the 2017 Middle Market 50 were awarded at the 2017 Middle Market 50 Awards Dinner at the Ritz Carlton in Dallas.

Headquartered in Addison, Texas, Solis currently operates 37 centers across six major markets – North Texas; Houston, Texas; Phoenix, Ariz.; Columbus, Ohio; Greensboro, N.C.; and, through its acquisition of Washington Radiology, the D.C. metropolitan area. The company operates both wholly-owned centers and multiple joint ventures with hospital partners. Solis Mammography (including Washington Radiology) serves more than 600,000 patients each year with highly-specialized breast imaging services including screening and diagnostic mammography (2-D and 3-D), computer-aided detection, breast ultrasound, stereotactic biopsy and ultrasound-guided biopsy.

Over the past three years, the company has committed $16 million to upgrade all of its centers with 3-D mammography (also known as digital breast tomosynthesis), lowering unnecessary recalls by 37 percent and increasing cancer detection by 54 percent. Taken together, these changes have earned the company a 76 percent annual retention rate with returning patients, far higher than the national average of 53 percent.

Under the leadership of James Polfreman, the company has more than doubled its footprint since he joined the company in 2011, increasing revenue by more than 250 percent and creating a fivefold increase in bottom line, earnings before interest, tax, depreciation and amortization (EBITDA).

For more information: www.solismammo.com

Related Content

Breast Cancer Patients Largely Find Radiation Therapy Experience Better Than Expected
News | Women's Health | September 25, 2017
A new survey finds breast cancer patients’ actual radiation therapy experiences largely exceeded their expectations....
Fujifilm Installing New DR Equipment for Three Large Healthcare Systems
News | Digital Radiography (DR) | September 22, 2017
Fujifilm Medical Systems U.S.A. Inc. recently closed new contracts to enhance diagnostic imaging capabilities for...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
DenseBreast-info.org Debuts  Spanish Language Video  About Dense Breasts
News | Breast Density | September 12, 2017
Breast cancer risks associated with breast density are the subject of a new Spanish language video launched recently by...
Asian Study Underlines Potential Value of Pressure-Guided Mammography
News | Mammography | September 11, 2017
Sigmascreening recently announced that a study of in total 15,898 in digital mammograms from 3,772 Asian women...
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
Breast imaging X-ray mammogram showing a breast tumor. Photo courtesy of Monthian Ritchan-Ad

Photo courtesy of Monthian Ritchan-Ad

Feature | Breast Density | September 08, 2017 | By Roy Prager, M.D.
While mammograms play a vital role in efforts to identify breast cancer, they can present some challenges in women with...
FDA Clears Senographe Pristina Mammography System With Patient-Assisted Compression
Technology | Mammography | September 05, 2017
The U.S. Food and Drug Administration (FDA) cleared GE Healthcare’s Senographe Pristina with Self-Compression, the...
FDA Releases Six-Month Inspection Data From EQUIP Mammography Quality Initiative
News | Mammography | September 01, 2017
September 1, 2017 — The Division of Mammography Quality Standards (DMQS) of the U.S.
Hologic Announces Availability of Brevera Breast Biopsy System With CorLumina Imaging Technology
Technology | Breast Biopsy Systems | August 31, 2017
Hologic Inc. announced U.S. commercial availability of the Brevera breast biopsy system with CorLumina imaging...
Overlay Init